Venture Philanthropy in Practice: Expanding the Corporate Relations Toolkit
By Tammy Eickhoff and Tracy Parish
Across academic institutions, corporate relations teams are increasingly asked to move beyond traditional sponsorships and transactional partnerships toward models that accelerate translation, de‑risk innovation, and align long‑term impact with external investment.
Venture philanthropy — while not always labeled as such — offers a useful lens for understanding how this shift is playing out in practice.
At our institutions, the Mayo Clinic and the University of Illinois’ Carl R. Woese Institute for Genomic Biology (IGB), elements of venture philanthropy are beginning to influence how corporate and industry relationships are identified, structured, and advanced.
Mayo Clinic: Mission driven collaboration
Mayo Clinic is intentionally mission‑driven. The value created through external partnerships across multiple departments in the organization supports continued investment in discovery, translational science, and clinical innovation —reinforcing a cycle in which collaboration fuels future patient impact.
While distinct from venture philanthropy in structure, this approach reflects similar characteristics: a long‑term orientation, disciplined stewardship of value, and an emphasis on strengthening institutional capabilities rather than maximizing short‑term return.
Within this framework, philanthropy — particularly in partnership with corporate and foundation stakeholders — serves as a powerful strategic tool. Funding through gifts and grants can support early discovery, validation, and de‑risking activities, creating a bridge to downstream industry engagement. For corporate relations officers, this capital becomes a mechanism for shaping the timing, structure, and intent of partnerships.
This approach also had a positive downstream effect on the institution’s broader strategy at Mayo Clinic. By investing early in talent and translational capacity through long‑term philanthropic vehicles such as endowment support and career development awards, Mayo Clinic strengthened the readiness of its innovation pipeline and expanded the range of partnership opportunities available over time.
Rather than anchoring corporate partnerships to a specific outcome, the model increased strategic optionality — enabling future corporate engagements to be pursued from a position of greater maturity, alignment, and institutional strength.
Relationships like this do not emerge accidentally; they reflect intentional corporate relations engagement focused on aligning capital, collaboration, and mission over the long term.
IGB: Mission‑Driven Innovation and Partnership Alignment
At the Carl R. Woese Institute for Genomic Biology, interdisciplinary research and mission‑driven innovation provide a natural foundation for venture‑philanthropy‑informed engagement.
While not branded explicitly as venture philanthropy, the institute’s emphasis on translational genomics, systems biology, and societal impact aligns well with partners seeking to support early‑stage science with downstream application potential.
For corporate relations teams, this means framing partnerships not only around sponsored research, but also around shared risk, co‑development pathways, and longer‑term innovation pipelines. Industry partners interested in genomics‑enabled solutions — whether in agriculture, health, or sustainability — can engage with IGB in ways that mirror venture philanthropy’s focus on catalytic investment and measurable impact.
An example of how the Carl R. Woese Institute for Genomic Biology is partnering with other units at Illinois to leverage the venture philanthropy approach is the Biomass Innovation Hub (BIH), a University of Illinois initiative that combines existing assets with new resources to jumpstart a biomass-to-manufactured product ecosystem in Central Illinois.
Miscanthus and related crops serve as the primary feedstocks for this initiative and offer scalable solutions across a variety of sectors, including energy, packaging, pet care, and more.
The BIH leverages multiple university resources to support workforce development and product innovation and is working with partners in agriculture to build a reliable supply chain. Currently funded through philanthropic support, the BIH aims to connect innovators with investors who will fund start-ups developing and scaling biomass-based products to stimulate economic growth and the expansion of the biomass-to-manufactured product ecosystem in Central Illinois and beyond.
Implications for Corporate Relations Professionals
Taken together, these examples highlight how venture philanthropy principles are increasingly relevant to academic corporate relations:
- Expanded roles for external experts who bridge academia, industry, and investment
- Earlier engagement around translational potential, not just mature technologies
- Deeper alignment between institutional mission and partner strategy
For NACRO members, the takeaway is clear: venture philanthropy is less a discrete funding model and more a mindset — one that corporate relations officers are well positioned to operationalize as institutions seek new pathways from discovery to impact.
Tammy Eickhoff is Co-Vice President of NACRO and Director of Corporate & Foundation Relations (CFR) and Assistant Professor of Health Care Administration with Mayo Clinic. Tracy Parish is Director of External Relations and Strategic Partnerships with the Carl R. Woese Institute for Genomic Biology at the University of Illinois Urbana-Champaign